C-reactive protein and lipoprotein-a as markers of coronary heart disease in polycystic ovary syndrome

Polikistik over sendromlu hastalarda koroner kalp hastalıklarının belirtecisi olarak c-reaktif protein ve lipoprotein-a bakılması

Nilgün Güdücü, Herman İşçi, Alın Başgül Yiğiter, İlkkan Dünder

Department of Obstetrics and Gynecology, İstanbul Bilim University Avrupa Florence Nightingale Hospital, İstanbul, Turkey

Abstract

Objective: The aim of this study was to investigate the risk factors of coronary heart disease, CRP and Lipoprotein-a in polycystic ovary syndrome patients.

Material and Methods: Prospectively collected data of polycystic ovary syndrome patients (n=62) and control group (n=40) were compared.

Results: PCOS patients had higher HOMA-IR, CRP, DHEAS, free testosterone, FAI, LH and prolactin levels when compared to the control group. Lipoprotein-a levels did not differ between the groups. The obese PCOS group had statistically significantly higher fasting blood glucose, total cholesterol, triglyceride, free testosterone, insulin, CRP and HOMA-IR and statistically significantly lower HDL and SHBG when compared to normal weight PCOS persons. Fasting blood glucose, total cholesterol, LDL, SHBG, CRP, Lipoprotein-a, FSH, LH, TSH, DHEAS and prolactin levels did not differ between the normal weight and obese control groups.

Conclusion: CRP levels increase in polycystic ovary syndrome patients and can be used as a marker of coronary heart disease. Future studies can be directed at treatments to decrease CRP levels, including antiinflammatory treatments.

Key words: Polycystic ovary syndrome, obesity, CRP, lipoprotein-a, coronary heart disease

Received: 09 May, 2012 Accepted: 12 November, 2012

Introduction

Polycystic ovarian syndrome (PCOS) is a heterogenous disease characterized by hyperandrogenism, chronic oligo-anovulation, infertility and insulin resistance (IR) (1). This common endocrinopathy, encountered in 5-10% of women of reproductive age (2), necessitates exclusion of other etiologies of hirsutism and anovulation. The wide-spectrum of the disease and the changing nature of the clinical presentation with weight fluctuations may be challenging. Most women with PCOS present with features of metabolic syndrome (MS), including abdominal obesity, IR, hypertension and dyslipidemia (3). PCOS patients were reported to have an increased prevalence of MS, about 2-3 times higher than age-matched controls (3, 4). Metabolic syndrome is a known risk factor for coronary heart disease (CHD), and PCOS patients are a group of young women with a high risk of early-onset CHD (5). In a recent study women with PCOS were reported to have an increased incidence of cardiovascular events and a lower event free survival (6). Lipoprotein-a (Lp-a) is a genetically determined LDL-like atherogenic lipoprotein (7). The aim of this study was to investigate the previously suggested biochemical markers of CHD in women with PCOS, namely C-reactive protein (CRP) and Lp-a (8, 9).

Material and Methods

This is a prospective cross-sectional study carried out in Istanbul Bilim University School of Medicine, Department of Obstetrics and Gynecology Clinics between April 2010
and December 2011. The study was in agreement with the Declaration of Helsinki, 1975 and all of the involved patients gave their informed consent. Some of the data used in this study was used in another study which has been reported previously.

The study group consisted of 62 women with PCOS and 40 healthy, normally menstruating women without any concomitant disease. All PCOS patients were diagnosed as PCOS according to the 2003 Rotterdam ESHRE/ASRM PCOS Consensus Workshop Group criteria (10) if at least two of the following criteria were present: oligo/amenorrhea, clinical or biochemical hyperandrogenism and PCO on ultrasonography. Clinical hyperandrogenism was defined as the presence of a Ferriman-Gallwey score > 8. PCO was defined as the presence of an ovary with 12 or more follicles measuring 2-9mm in diameter. All subjects in the control group had a normal pelvic ultrasound, regular periods and no clinical or biochemical hyperandrogenism. Patients with systemic diseases such as diabetes mellitus, cardiovascular diseases, hypertension, thyroid diseases, chronic renal failure, malignancy, Cushing syndrome, congenital adrenal hyperplasia, hyperprolactinemia and gastrointestinal malabsorptive diseases were excluded. None of the patients were on any medications for at least 3 months before the study including oral contraceptives, glucocorticoids, lipid-lowering, antiobesity, antidiabetes, antiandrogenic, antihypertensive or ovulation-inducing agents.

All the patients underwent a physical examination and appropriate laboratory tests were performed. BMI was calculated as body weight in kilograms divided by height in square metres (kg/m²). Patients were also separated into two groups according to their body mass index (BMI). Twenty-one patients with PCOS were obese (BMI ≥ 25) and 41 were non-obese (BMI < 25). In the control group, 11 patients were obese (BMI ≥ 25) and 29 were non-obese (BMI < 25). Weight, height and waist and hip circumferences were measured. Waist circumference (WC) was obtained as the smallest circumference at the level of the umbilicus. Hip circumference (HC) was obtained as the widest circumference at the level of the buttocks. Serum samples were obtained from all women in the early follicular phase after an overnight fast, during the 3rd-4th days of the cycle. Levels of fasting plasma glucose, insulin, total cholesterol, high-density lipoprotein (HDL), low density lipoprotein (LDL), triglycerides (TG), LH, FSH, prolactin, TSH, dehydroepiandrosterone sulfate (DHEAS), free testosterone, cortisol, freeT4, 17-OH progest-}

| Table 1. Anthropometric, biochemical and hormonal characteristics of the study groups |
|---------------------------------|----------------|----------------|---|
|                                  | PCOS n=62 | Control n=40 | p  |
| Age (years)                      | Mean±SD (Median) | Mean±SD (Median) | 0.002** |
| Height (cm)                      | 24.77±4.85   | 28.13±5.66   |    |
| Weight (kg)                      | 64.60±14.88  | 61.82±14.69  | 0.357 |
| Waist/Hip ratio                  | 0.81±0.09    | 0.79±0.06    | 0.197 |
| BMI (kg/m²)                      | 24.15±5.35   | 23.5±5.33    | 0.465 |
| Fasting glucose (mg/dL)          | 91.95±6.99   | 90.35±7.22   | 0.267 |
| Insulin (uU/mL)                  | 11.41±6.89   | 8.73±3.85    | 0.014* |
| Total Cholesterol (mg/dL)        | 162.39±36.32 | 162.41±28.92 | 0.998 |
| Triglyceride (mg/dL)             | 69.23±30.30  | 65.67±25.23  | 0.540 |
| HDL (mg/dL)                      | 56.60±15.97  | 54.42±13.67  | 0.479 |
| LDL (mg/dL)                      | 93.62±27.24  | 99.70±27.24  | 0.275 |
| +DHEAS (ug/dL)                   | 273.98±109.45 (280.55) | 235.63±103.69 (219.00) | 0.036* |
| +F. Testosterone (ng/dL)         | 0.73±0.54 (0.63) | 0.38±0.23 (0.30) | 0.001** |
| FSH (mIU/mL)                     | 5.46±1.39    | 6.87±2.08    | 0.001** |
| LH (mIU/mL)                      | 8.72±4.17    | 6.15±2.50    | 0.001** |
| Prolactin (ng/mL)                | 20.87±9.21   | 16.53±6.16   | 0.006** |
| TSH (uU/mL)                      | 2.43±1.221   | 2.13±1.07    | 0.198 |
| HOMA-IR                          | 2.58±1.71    | 2.01±1.07    | 0.042* |
| +SHBG (nmol/mL)                  | 44.44±25.5 (35.59) | 50.39±22.98 (42.42) | 0.029* |
| FAI                              | 4.31±2.78    | 2.36±1.52    | 0.017* |
| +Lipoprotein-a (mg/dL)           | 24.69±20.05 (18) | 22.11±28.77 (9.7) | 0.097 |
| +CRP (mg/dL)                     | 0.27±0.28 (0.16) | 0.19±0.25 (0.10) | 0.046* |

Student t Test, +Mann Whitney U Test, *p<0.05, **p<0.01
terone, sex-hormone binding globulin (SHBG), CRP (cobas integra 400, Roche) and Lp-a (cobas integra 800, Roche) were measured. Insulin resistance was calculated by the homeostasis model assessment (HOMA) index with the formula: HOMA-IR=fasting plasma immunoreactive insulin (μU/mL)x fasting serum glucose (mg/dL)/405, after excluding those with a serum glucose>200mg/dL, using insulin and thiazolidine.

Statistical analyses were performed using the Number Cruncher Statistical System (NCSS) 2007& Power Analysis and Sample Size (PASS) 2008 Statistical Software (Utah). Data showing normal distribution of parameters were compared with the Student's t-test, data showing non-normal distribution of parameters were compared with Mann Whitney U test, relation of CRP and Lp-A with other parameters was compared with Spearman’s correlation analysis. At a confidence interval of 95%, p-values<0.05 were considered statistically significant.

Results

The anthropometric, biochemical and hormonal data of the groups were shown in Table 1. BMI, waist to hip ratio (WHR), fasting plasma glucose, total cholesterol, TG, HDL, LDL, lipoprotein-a (Lp-a), insulin and TSH levels were similar in the PCOS and control groups. PCOS patients had higher HOMA-IR, CRP, DHEAS, free testosterone, FAI, LH and prolactin levels when compared to the control group and lower FSH and SHBG levels. Lp-a levels did not differ between the groups.

Lp-a correlated negatively with DHEAS and positively with LDL in the control group, but did not correlate with any parameter in women with PCOS (Table 2). CRP correlated positively with weight, BMI, insulin, LDL and HOMA-IR in women with PCOS, with weight, WHR, BMI, insulin, TG and HOMA-IR in the control group and correlated negatively with HDL in the control group (Table 2).

The obese PCOS group had statistically significantly higher fasting blood glucose, total cholesterol, triglyceride, free testosterone, insulin, CRP and HOMA-IR and statistically significantly lower LDL and SHBG when compared to the normal weight PCOS controls (Table 3). Lp-a, FSH, LH, TSH, DHEAS and prolactin levels did not differ between the PCOS groups (Table 3). Obese controls had statistically significantly higher triglyceride, insulin, free testosterone and HOMA-IR and statistically significantly lower HDL when compared to normal weight controls (Table 4). Fasting plasma glucose, total cholesterol, LDL, SHBG, CRP, Lp-a, FSH, LH, TSH, DHEAS and prolactin levels did not differ between the normal weight and obese control groups (Table 4).

Table 2. Correlations according to Lipoprotein-a and CRP between the groups

|                      | Lipoprotein-a | CRP |
|----------------------|---------------|-----|
|                      | PCOS          | Control | PCOS    | Control |
|                      | r   | p   | r   | p   | r   | p   | r   | p   |
| Age                  | -0.111 | 0.400 | 0.159 | 0.335 | -0.056 | 0.672 | 0.186 | 0.250 |
| Weight               | 0.127 | 0.337 | 0.229 | 0.162 | 0.411 | 0.001** | 0.457 | 0.003** |
| Waist/Hip ratio      | 0.049 | 0.711 | 0.231 | 0.158 | 0.032 | 0.808 | 0.314 | 0.049* |
| Height               | 0.155 | 0.241 | -0.049 | 0.769 | -0.053 | 0.689 | 0.041 | 0.800 |
| BMI                  | 0.094 | 0.480 | 0.252 | 0.121 | 0.389 | 0.002** | 0.503 | 0.001** |
| Fasting glucose      | -0.026 | 0.847 | 0.051 | 0.760 | 0.189 | 0.147 | 0.202 | 0.212 |
| Insulin              | 0.143 | 0.285 | 0.209 | 0.202 | 0.421 | 0.001** | 0.453 | 0.003** |
| T. Cholesterol       | 0.115 | 0.474 | 0.095 | 0.625 | 0.267 | 0.092 | 0.041 | 0.833 |
| Triglyceride         | -0.008 | 0.950 | 0.148 | 0.367 | 0.113 | 0.390 | 0.404 | 0.010* |
| HDL                  | 0.156 | 0.239 | -0.223 | 0.173 | -0.090 | 0.495 | -0.325 | 0.041* |
| LDL                  | -0.017 | 0.899 | 0.333 | 0.038* | 0.295 | 0.022* | -0.025 | 0.877 |
| DHEAS                | -0.022 | 0.868 | -0.407 | 0.010* | 0.172 | 0.189 | 0.073 | 0.657 |
| F. Testosterone      | -0.252 | 0.056 | -0.063 | 0.706 | 0.151 | 0.253 | 0.256 | 0.116 |
| FSH                  | 0.155 | 0.245 | 0.157 | 0.340 | 0.086 | 0.518 | -0.016 | 0.920 |
| LH                   | -0.052 | 0.697 | 0.078 | 0.639 | -0.017 | 0.900 | 0.004 | 0.980 |
| Prolactin            | -0.064 | 0.638 | -0.242 | 0.138 | -0.058 | 0.667 | -0.202 | 0.211 |
| TSH                  | -0.233 | 0.078 | 0.031 | 0.849 | -0.123 | 0.354 | 0.051 | 0.756 |
| HOMA-IR              | 0.169 | 0.200 | 0.232 | 0.156 | 0.372 | 0.003** | 0.467 | 0.002** |
| SHBG                 | 0.086 | 0.697 | 0.191 | 0.273 | -0.234 | 0.271 | -0.150 | 0.384 |
| FAI                  | -0.122 | 0.571 | -0.252 | 0.384 | 0.170 | 0.416 | 0.059 | 0.834 |

r: Spearman’s correlations, *p<0.05, **p<0.01
Table 3. Comparison of parameters according to BMI in PCOS patients

| n=62 | BIM<25 | BIM>25 | p |
|------|--------|--------|---|
|      | Mean±SD (median) | Mean±SD (median) |   |
| Fasting glucose (mg/dL) | 90.39±5.98 (89.50) | 95±7.92 (94.20) | 0.131* |
| Insulin (uU/mL) | 9.14±5.26 | 16.07±7.61 (15.90) | 0.000** |
| T. Cholesterol (mg/dL) | 153.75±27.09 | 181±46.87 | 0.023* |
| Triglyceride (mg/dL) | 62.61±22.03 (61.30) | 82.80±39.88 (81.50) | 0.045* |
| HDL (mg/dL) | 59.49±16.63 | 50.70±12.98 (50.50) | 0.043* |
| FSH (mIU/mL) | 5.49±1.57 | 5.43±0.98 (5.30) | 0.859 |
| LDL (mg/dL) | 87.32±3.41 | 106.55±32.82 (105.30) | 0.008** |
| ^DHEAS (ug/dL) | 266.60±114.04 (282.10) | 288.40±101 (278) | 0.337 |
| ^F. Testosterone (ng/dL) | 0.59±0.45 (0.50) | 1.03±0.59 (0.87) | 0.001** |
| LH (mIU/mL) | 9.30±4.48 | 7.62±3.35 (7.50) | 0.138 |
| Prolactin (ng/mL) | 22.23±10 | 18.33±7.06 | 0.119 |
| TSH (uU/mL) | 2.27±1.04 | 2.73±1.46 | 0.211 |
| HOMA-IR | 1.95±1.02 | 3.80±2.11 (3.60) | 0.002** |
| ^SHBG (nmol/mL) | 57.90±24.50 (47.30) | 24.24±6.71 (23.61) | 0.001** |
| FAI | 3.04±1.66 | 6.35±3.07 (6.20) | 0.002** |
| ^Lipoprotein-a (mg/dL) | 24.64±20.55 (18.50) | 24.80±19.49 (17.60) | 0.542 |
| ^CRP (mg/dL) | 0.20±0.24 (0.11) | 0.42±0.31 (0.42) | 0.001** |

Student t Test, ^Mann Whitney U Test, *p<0.05, **p<0.01

Table 4. Comparison of parameters according to BMI in the control group

| n=40 | BIM<25 | BIM>25 | p |
|------|--------|--------|---|
|      | Mean±SD | Mean±SD |   |
| Fasting glucose (mg/dL) | 89.90±5.90 | 91.55±10.19 | 0.526 |
| Insulin (uU/mL) | 7.8±3.18 | 11.13±4.56 | 0.013* |
| T. Cholesterol (mg/dL) | 161.64±28.62 | 164.86±32.06 | 0.803 |
| Triglyceride (mg/dL) | 59.00±19.67 | 83.27±30.50 | 0.005** |
| HDL (mg/dL) | 59.49±16.63 | 50.70±12.98 (50.50) | 0.009** |
| FSH (mIU/mL) | 5.49±1.57 | 5.43±0.98 (5.30) | 0.859 |
| LDL (mg/dL) | 87.32±3.41 | 106.55±32.82 (105.30) | 0.008** |
| ^DHEAS (ug/dL) | 266.60±114.04 (282.10) | 288.40±101 (278) | 0.337 |
| ^F. Testosterone (ng/dL) | 0.34±0.22 (0.30) | 0.51±0.24 (0.33) | 0.035* |
| LH (mIU/mL) | 9.30±4.48 | 7.62±3.35 (7.50) | 0.138 |
| Prolactin (ng/mL) | 22.23±10 | 18.33±7.06 | 0.119 |
| TSH (uU/mL) | 2.27±1.04 | 2.73±1.46 | 0.211 |
| HOMA-IR | 1.95±1.02 | 3.80±2.11 (3.60) | 0.002** |
| ^SHBG (nmol/mL) | 57.90±24.50 (47.30) | 24.24±6.71 (23.61) | 0.001** |
| FAI | 3.04±1.66 | 6.35±3.07 (6.20) | 0.002** |
| ^Lipoprotein-a (mg/dL) | 24.64±20.55 (18.50) | 24.80±19.49 (17.60) | 0.542 |
| ^CRP (mg/dL) | 0.20±0.24 (0.11) | 0.42±0.31 (0.42) | 0.001** |

Student t Test, ^Mann Whitney U Test, *p<0.05, **p<0.01
Discussion

Although there is no standard evaluation for cardiovascular risk assessment, CRP is a known predictor of future CHD risk (11) and Lp-a was reported to be associated with coronary heart disease (9). High sensitivity CRP is a marker of inflammation, an acute phase reactant that is synthesized in the liver as a response to tumor necrosis factor-a (TNF-a) and interleukin-6 (11). CRP was also shown to play a role in cardiovascular events by complement activation, adhesion molecule expression and promotion of LDL uptake by macrophages (12). In this study, we detected increased CRP levels in PCOS patients, as reported previously (13,14). In our study, PCOS patients had statistically significantly increased CRP levels and obese PCOS patients had higher CRP levels than non-obese PCOS. We did not find such a relationship in the control group. Both non-obese and obese PCOS were reported to have higher CRP concentrations when compared to the control groups with similar BMI (8, 15). Gen et al. (16) reported similar CRP levels in non-obese PCOS and healthy women. These findings suggest an increased body weight as the major determinant of metabolic abnormalities related to CHD in PCOS women, as reported previously (16, 17) and CRP as the marker of increased CHD risk.

A significant correlation was previously reported between CRP and IR in PCOS patients (13-15). In our study, CRP correlated with IR both in PCOS patients and control group. In PCOS patients correlation of CRP with IR was independent of WHR, but in the control group it was related to the presence of abdominal obesity. These findings suggest an increased risk of CHD in PCOS patients independent of abdominal obesity. Hyperandrogenic women not fulfilling PCOS criteria were reported to have CRP levels similar to the control group (18). There was no correlation between CRP levels and androgens in our study, as reported previously (13).

We hypothesized that by measuring Lp-a levels, cardiovascular risk factors not related to insulin resistance could be determined and treatment strategies could be developed. We found similar Lp-a levels in PCOS patients and healthy controls without concomitant disease. Moreover Lp-a plasma levels showed no variation when groups were compared according to the BMI and had no correlation with other metabolic parameters. Patients with MS, a syndrome with features similar to PCOS, were reported to have higher Lp-a levels when compared to the control group (19). Previously, PCOS patients were shown to have increased concentrations of Lp-a (9). In our study there was no difference in Lp-a levels between PCOS patients and controls. Elevated plasma levels of Lp-a have been suggested to increase the risk of CHD in a way independent of insulin resistance (20). Other studies suggested modifications in Lp-a by glycation, this modification was reported to increase the risk of CHD both in type 1 and type 2 diabetic women (9, 21, 22). Obese PCOS were reported to have higher Lp-a levels when compared to non-obese PCOS, while other studies found elevated Lp-a both in non-obese and obese PCOS (23, 24). In our study, there was no correlation between Lp-a levels and IR markers. In our control group, Lp-a levels correlated positively with LDL and negatively with DHEAS levels. These findings obscure the suggestion of Lp-a as a marker of CHD in PCOS patients. As Lp-a is genetically and racially determined (7), these findings may be unique to our population.

Insulin resistance is a common feature of PCOS, it affects about half the women with PCOS, whether obese or non-obese (25). PCOS patients were reported to have a form of IR intrinsic to PCOS (26). Forty percent of obese PCOS patients developed diabetes or impaired glucose tolerance until the age of 26 years (27). Obesity acts as an additive factor, increasing IR (25). Our PCOS patients had higher IR when compared to the control group.

Conclusion

CRP levels were increased in PCOS patients and the increase was higher in obese PCOS patients. Weight loss may decrease CHD risk in PCOS patients and CRP can be used as a marker of CHD. The role of antiinflammatory drugs in decreasing CRP and CHD of PCOS patients can be studied in the future clinical trials.

Conflict of interest
No conflict of interest was declared by the authors.

References

1. Lobo RA, Carmina E. The importance of diagnosing the polycystic ovary syndrome. Ann Intern Med 2000; 132: 989-93. [CrossRef]  
2. Franks S. Polycystic ovary syndrome. N Engl J Med 1995; 333: 853-61. [CrossRef]  
3. Apridonidze T, Essah PA, luorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90: 1929-35. [CrossRef]  
4. Ehrmann DA, Liljenquist DR, Kasza K, Aziz R, Legro RS, Ghazzi MN, et al. Prevalence and predictors of metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91: 48-53. [CrossRef]  
5. Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve-Smith L. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism 2003; 52: 908-15. [CrossRef]  
6. Shaw LJ, Bairey Merz CN, Aziz R, Stanczyk FZ, Sopko G, Braunstein GD, et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health-national Heart, Lung, and Blood Institute sponsored Women’s Ischemia Syndrome Evaluation. J Clin Endocrinol Metab 2008; 93: 1276-84. [CrossRef]  
7. Scannu AM. Lipoprotein (a). A genetic risk factor for premature coronary heart disease. JAMA 1992; 267: 3326-9. [CrossRef]  
8. Boulman N, Levy Y, Leiba R, Shachar S, Linn R, Zinder O, Blumenfeld Z. Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab 2004; 89: 2160-5. [CrossRef]  
9. Bernesi K, Rizzo M, Hersberger M, Rini GB, Di Fede G, Pepe I, et al. Atherogenic forms of dyslipidemia in women with polycystic ovary syndrome. Int J Clin Pract 2009; 63: 56-62. [CrossRef]  
10. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19-25. [CrossRef]  
11. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of
C-reactive protein and other markers of inflammation in the prediction of first cardiovascular event. N Engl J Med 2002; 347: 1557-65.

12. Blake GJ, Ridker PM. Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med. 2002; 252: 283-94. [CrossRef]

13. Kelly C, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2001; 86: 2453-5. [CrossRef]

14. Fenkci V, Fenkci S, Yılmazer M, Serteser M. Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. Fertil Steril 2003; 80: 123-7. [CrossRef]

15. Tarkun I, Arslan BC, Canturk Z, Turemen E, Sahin T, Duman C. Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation. J Clin Endocrinol Metab 2004; 89: 5592-96. [CrossRef]

16. Gen R, Akbay E, Muslu N, Sezer K, Cayan F. Plasma visfatin level in lean women with PCOS: relation to proinflammatory markers and insulin resistance. Gynecol Endocrinol 2009; 25: 241-5. [CrossRef]

17. Möhlig M, Spranger J, Osterhoff M, Ristow M, Pfeiffer AF, Schill T, et al. The polycystic ovary syndrome per se is not associated with increased chronic inflammation. Eur J Endocrinol 2004; 150: 525-32. [CrossRef]

18. Tosi F, Dorizzi R, Castello R, Maffeis C, Spiazzi G, Zoppini G, et al. Body fat and insulin resistance independently predict increased serum C-reactive protein in hyperandrogenic women with polycystic ovary syndrome. Eur J Endocrinol 2009; 161: 737-45. [CrossRef]

19. Bozbaş H, Yildirim A, Pirat B, Eroğlu S, Korkmaz ME, Atar I, et al. Increased lipoprotein(a) in metabolic syndrome: Is it a contributing factor to premature atherosclerosis? The Anatolian Journal of Cardiology 2008; 8: 111-5.

20. Onat A, Hergenc G, Ozhan H, Kaya Z, Bulur S, Ayhan E, et al. Lipoprotein(a) is associated with coronary heart disease independent of metabolic syndrome. Coron Artery Dis 2008; 19: 125-31. [CrossRef]

21. Starkman HS, Cable G, Hala V, Hecht H, Donnelly CM. Delineation of prevalence and risk factors for early artery disease by electron beam computed tomography in young adults with type 1 diabetes. Diabetes Care 2003; 26: 433-6. [CrossRef]

22. Qasim AN, Martin SS, Mehta NN, Wolfe ML, Park J, Shcwartz S, et al. Lipoprotein(a) is strongly associated with coronary artery calcification in type-2 diabetic women. Int J Cardiol 2011; 150: 17-21. [CrossRef]

23. Yılmaz M, Biri A, Bukan N, Karakoç A, Sancak B, Toruner F, et al. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome. Gynecol Endocrinol 2005; 20: 258-63. [CrossRef]

24. Rizzo M, Berneis K, Hersberger M, Pepe I, Di Fede G, Rini GB, et al. Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype. Hum Reprod 2009; 24: 2286-92. [CrossRef]

25. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989; 38: 1165-74. [CrossRef]

26. Diamanti-Kandarakis E. Insulin resistance in PCOS. Endocrine 2006; 30: 13-7. [CrossRef]

27. Talbott EO, Zborowski JV, Sutton-Tyrrell K, McHugh-Pemu KP, Guzick DS. Cardiovascular risk in women with polycystic ovary syndrome. Obstet Gynecol Clin North Am 2001; 28: 111-33. [CrossRef]